Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Smoldering Multiple Myeloma (SMM)”

110 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 110 results

Early research (Phase 1)Looking for participantsNCT05055063
What this trial is testing

With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

Who this might be right for
Myeloma
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT02316106
What this trial is testing

Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 123
Testing effectiveness (Phase 2)Active Not RecruitingNCT03236428
What this trial is testing

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Who this might be right for
Monoclonal GammopathySmoldering Multiple Myeloma
Dana-Farber Cancer Institute 42
Early research (Phase 1)Active Not RecruitingNCT02886065
What this trial is testing

PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Who this might be right for
Smoldering Multiple Myeloma
Massachusetts General Hospital 19
Not applicableUnknownNCT05047107
What this trial is testing

Biology and Genetics of Smouldering Myeloma

Who this might be right for
Smouldering MyelomaMGUSMultiple Myeloma
University College, London 500
Testing effectiveness (Phase 2)Looking for participantsNCT05469893
What this trial is testing

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Who this might be right for
High-risk Smoldering Multiple MyelomaSmoldering Multiple MyelomaMultiple Myeloma
Irene Ghobrial, MD 52
Early research (Phase 1)Study completedNCT02697383
What this trial is testing

Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study

Who this might be right for
Multiple MyelomaHigh Risk Smoldering Multiple Myeloma
Memorial Sloan Kettering Cancer Center 14
Not applicableLooking for participantsNCT03616483
What this trial is testing

The Indiana Myeloma Registry

Who this might be right for
Plasma Cell Dyscrasias
Indiana University 2,500
Testing effectiveness (Phase 2)Ended earlyNCT01248455
What this trial is testing

A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma

Who this might be right for
Multiple MyelomaMyelomaSmoldering Multiple Myeloma
National Cancer Institute (NCI) 9
Not applicableWithdrawnNCT02298816
What this trial is testing

B-Cell Hematologic Malignancy Vaccination Registry

Who this might be right for
Monoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaWaldenstrom Macroglobulinemia+4 more
Wake Forest University Health Sciences
Not applicableEnded earlyNCT01109407
What this trial is testing

Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)

Who this might be right for
Smoldering MyelomaMonoclonal Gammopathy of Undetermined Significance
National Cancer Institute (NCI) 225
Early research (Phase 1)UnknownNCT02240537
What this trial is testing

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer

Who this might be right for
Acute Myelogenous Leukemia (AML)Multiple Myeloma (MM)Myelodysplastic Syndrome (MDS)+1 more
Benovus Bio, Inc. 4
Not applicableLooking for participantsNCT05136807
What this trial is testing

Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

Who this might be right for
Monoclonal Gammopathy of Undetermined SignificanceSmoldering Plasma Cell Myeloma
M.D. Anderson Cancer Center 400
Not applicableStudy completedNCT01955395
What this trial is testing

Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma

Who this might be right for
Monoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple Myeloma
Dana-Farber Cancer Institute 93
Not applicableUnknownNCT04727294
What this trial is testing

MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey

Who this might be right for
Multiple MyelomaSmoldering Multiple MyelomaMonoclonal Gammopathy of Undetermined Significance+1 more
HealthTree Foundation 1,500
Testing effectiveness (Phase 2)Active Not RecruitingNCT02415413
What this trial is testing

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

Who this might be right for
Smoldering Multiple Myeloma
PETHEMA Foundation 90
Testing effectiveness (Phase 2)WithdrawnNCT01571726
What this trial is testing

Imaging Studies and the Development of Multiple Myeloma

Who this might be right for
Multiple MyelomaSmoldering Multiple MyelomaMonoclonal Gammopathy of Undetermined Significance
National Cancer Institute (NCI)
Large-scale testing (Phase 3)Study completedNCT00480363
What this trial is testing

QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression

Who this might be right for
Multiple Myeloma
PETHEMA Foundation 120
Not applicableLooking for participantsNCT05640843
What this trial is testing

A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

Who this might be right for
Monoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple Myeloma
Memorial Sloan Kettering Cancer Center 180
Testing effectiveness (Phase 2)Active Not RecruitingNCT04933539
What this trial is testing

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

Who this might be right for
Multiple Myeloma
National Cancer Institute (NCI) 14
Load More Results